iSono Health's FDA-cleared wearable puts a 3D breast scanner in the clinic

The Sunnyvale startup's hardware and AI system, designed for use by nurses, has secured commercial partnerships across the Middle East, Africa, and Asia.

About iSono Health

Published

For a woman with a suspicious lump, the path to a diagnosis often runs through a radiology department, a waiting list, and a trained sonographer. The bottleneck is not just the machine, but the specialist required to operate it. iSono Health, a Sunnyvale-based medical device company, is betting that a piece of wearable hardware and some carefully tuned software can change that equation, moving breast imaging out of the specialist suite and into the point-of-care clinic [Perplexity Sonar Pro Brief].

Its product, called ATUSA, is a portable, automated 3D breast ultrasound system that received FDA clearance in 2022 [Businesswire, May 2022]. The company states the device is now commercially released, combining a wearable scanner, automated image acquisition, and AI-powered software into what it calls a "virtual sonographer" [iSono Health press page, November 2026]. The clinical wedge is operator independence: the system is designed for use by physicians, nurses, or medical assistants, not specialist sonographers, and can complete a scan of both breasts in about four minutes, hands-free [iSono Health].

The hardware and regulatory wedge

The core of iSono's bet is a shift in workflow, enabled by hardware. ATUSA consists of a wearable scanner that automates the 3D ultrasound sweep, a Windows application for image display, and a secure web portal for remote viewing [Perplexity Sonar Pro Brief]. By standardizing the image acquisition process, the company aims to produce consistent, repeatable 3D images that can be used for screening and monitoring, particularly in settings where access to trained sonographers or large, fixed ultrasound systems is limited.

The FDA's 510(k) clearance in May 2022 was a critical, non-negotiable milestone. It provides the regulatory foundation for commercial sales in the United States and serves as a key credential for international expansion. For a device that deliberately removes a highly trained human from the imaging loop, that clearance is a significant vote of confidence in the system's safety and its ability to produce diagnostically useful images.

A founder-built path to market

The company's journey from concept to cleared device appears to have been deeply founder-led. CEO Maryam Ziaei, who holds a PhD, is credited with leading iSono Health from initial concept through hardware and AI development, multi-site clinical trials, the FDA clearance process, and now commercial launch [Perplexity Sonar Pro Brief]. Her background includes reviewing grants for the National Institutes of Health, giving her an insider's view of the non-dilutive funding landscape crucial for early-stage biotech [Crunchbase]. Co-founder and CTO Shadi Saberi brought over a decade of hardware engineering experience from companies like Broadcom and Intel to the task of building a wearable medical device [Crunchbase].

This technical founder pairing has navigated a complex funding mix. The company reports a total of $14.7 million in venture capital and Small Business Innovation Research (SBIR) grants [iSono Health press page, November 2026]. Other sources break this down further, citing approximately $7.7 million in equity financing and $3.7 million in non-dilutive grants from the NIH, National Cancer Institute (NCI), and NSF [WISH profile, November 2025]. Investors include Draper Associates, which led a $3 million seed round, and JSK Investments Group, which participated in an undisclosed round in October 2025 [Startup/jobs database] [Vestbee, October 2025].

Funding Component Reported Amount Source / Type
Total Venture & SBIR Funding $14.7 million Company report [iSono Health, November 2026]
Equity Financing $7.7 million (estimated) WISH profile [November 2025]
Non-dilutive Grants (NIH, NCI, NSF) $3.7 million (estimated) WISH profile [November 2025]
Seed Round (led by Draper Associates) $3 million Startup/jobs database

Traction and a global distribution play

Commercial momentum is building, though the evidence points more to pipeline than to widespread installed base. The company has established a significant commercial distribution partnership with Abdul Latif Jameel Health, covering 31 countries across the Middle East, North Africa, Africa, South Asia, and Southeast Asia [Perplexity Sonar Pro Brief]. A November 2025 profile reported a pipeline of approximately 600 customers, though it did not name specific health systems or document completed sales [WISH profile, November 2025].

The partnership strategy reveals iSono's initial market focus. By targeting regions with documented gaps in specialist access and imaging infrastructure, the company is deploying its technology where the operator-independence value proposition is theoretically strongest. The bet is that clinics and physician offices in these markets will adopt ATUSA to bring breast imaging in-house, reducing patient referral delays.

The clinical evidence question

The most credible counterfactual for iSono Health does not concern competition, but clinical validation. While FDA clearance is a substantial hurdle, it is primarily a safety and substantial equivalence determination. The broader medical community will want to see peer-reviewed studies demonstrating that images acquired by a nurse using ATUSA are as diagnostically accurate as those acquired by a certified sonographer using a conventional system for specific use cases, like screening dense breast tissue.

The company notes its funding supports ongoing NIH-backed clinical studies, but the available public material does not detail those study designs or endpoints [Perplexity Sonar Pro Brief]. Until such data is published, adoption by large, risk-averse health systems in the U.S. may proceed cautiously. The company's most plausible answer is already in motion: using its commercial partnerships to generate real-world evidence and outcomes data from the thousands of scans its system will perform.

The standard of care, and what comes next

For the millions of women who require breast ultrasound each year, the standard of care remains a visit to a radiology department. There, a sonographer manually guides a transducer across the breast, a process that is both operator-dependent and time-intensive. iSono Health's ambition is to collapse that workflow, making a reproducible 3D scan as routine in a primary care office as taking a blood pressure reading.

The next twelve months will be about translating pipeline into installed base and early data into clinical credibility. Key milestones to watch include the first published clinical validation studies from its NIH-backed trials and concrete sales figures emerging from its expansive 31-country distribution partnership. For the patient population with limited access to specialist imaging, the promise is a faster path to an answer. The company's task is now to prove that its automated hand can deliver that answer reliably.

Sources

  1. [Businesswire, May 2022] iSono Health ATUSA System Receives U.S. FDA Clearance for Breast Imaging | https://www.businesswire.com/news/home/20220517005242/en/
  2. [iSono Health press page, November 2026] iSono Health - Say Hello to ATUSA | https://isonohealth.com/
  3. [iSono Health] Product claims for ATUSA system | https://isonohealth.com/
  4. [Crunchbase] Maryam Ziaei-Moayyed and Shadi Saberi profiles | https://www.crunchbase.com
  5. [WISH profile, November 2025] iSono Health funding and pipeline details | https://wish.com/
  6. [Startup/jobs database] iSono Health seed round reporting | https://startupintros.com/orgs/isono-health
  7. [Vestbee, October 2025] JSK Investments backs iSono Health | https://vestbee.com/
  8. [LinkedIn, 2026] Maryam Ziaei and Shadi Saberi profiles | https://www.linkedin.com

Read on Startuply.vc